Watanabe M, Ohishi T, Kuzuoka M, Nudelman E D, Stroud M R, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y
Biomembrane Institute, Seattle 98119.
Cancer Res. 1991 Apr 15;51(8):2199-204.
A murine monoclonal antibody (MAb), NCC-ST-421 (IgG3), was raised by using a human gastric cancer xenograft St-4 as immunogen. Immunization was achieved by transferring immunocompetent normal BALB/c mouse spleen cells into BALB/c-nu/nu mice bearing St-4 tumors. Hybridomas were produced from spleen cells of the mice after rejection of the tumors and were screened for preferential reactivity with cancers on formalin-fixed paraffin sections, as described previously for establishment of MAb NCC-ST-439 (M. Watanabe et al., Jpn. J. Cancer Res., 76: 43-52, 1985). The immunobiological and immunochemical properties of the new MAb NCC-ST-421 are described here. The MAb is essentially directed to a structure with dimeric Le(a) (V4III4Fuc2Lc6Cer) epitope (Gal beta 1----3[Fuc alpha 1----4]GlcNAc beta 1----3Gal beta 1----3[Fuc alpha 1----4]GlcNAc beta 1----3Gal beta 1----4Glc beta 1----1 Cer). It cross-reacts with Le(a) but does not show any effect on Le(a)-positive RBC in vitro or on Le(a)-positive tissue loci in vivo. ST-421 strongly induced antibody-dependent cellular cytotoxicity using human peripheral blood leukocytes as effector cells with a variety of human tumor cells, using the short-term 51Cr release assay. It also showed striking complement-dependent cytotoxicity with a human complement source and was able to produce lysis of a variety of human cancer cell lines, supporting its observed ability to cause cytotoxic suppression of tumor growth in nude mice. In another series of experiments, i.p. injection of ST-421 completely inhibited growth of human tumor xenografts in nu/nu mice, and this inhibitory activity was closely dependent on expression of the dimeric Le(a) antigen on the cell surface. While Le(a) antigen was expressed in the kidneys of nu/nu mice, infusion of ST-421 in these mice did not cause histological change in kidney tissue. This finding suggests that the MAb does not damage normal cells or tissues which contain cross-reacting Le(a) antigen. These results demonstrate that ST-421 exerts a significant antitumor effect in vitro as well as in vivo, does not affect Le(a) antigen expressed on normal tissues, and therefore has potential application in therapy of certain types of human cancer which express the dimeric Le(a) antigen.
以人胃癌异种移植瘤St-4作为免疫原制备了鼠单克隆抗体(MAb)NCC-ST-421(IgG3)。通过将具有免疫活性的正常BALB/c小鼠脾细胞转移到携带St-4肿瘤的BALB/c-nu/nu小鼠体内实现免疫。在肿瘤消退后,从小鼠脾细胞中产生杂交瘤,并如先前建立MAb NCC-ST-439(M. Watanabe等人,《日本癌症研究杂志》,76: 43 - 52,1985年)所述,在福尔马林固定石蜡切片上筛选与癌症的优先反应性。本文描述了新的单克隆抗体NCC-ST-421的免疫生物学和免疫化学特性。该单克隆抗体主要针对具有二聚体Le(a)(V4III4Fuc2Lc6Cer)表位(Galβ1----3[Fucα1----4]GlcNAcβ1----3Galβ1----3[Fucα1----4]GlcNAcβ1----3Galβ1----4Glcβ1----1 Cer)的结构。它与Le(a)发生交叉反应,但在体外对Le(a)阳性红细胞或体内对Le(a)阳性组织位点没有任何影响。使用人外周血白细胞作为效应细胞和多种人肿瘤细胞,通过短期51Cr释放试验,ST-421强烈诱导抗体依赖性细胞毒性。它还显示出用人补体来源时显著依赖补体的细胞毒性,并且能够使多种人癌细胞系发生裂解,支持其在裸鼠中观察到的引起肿瘤生长细胞毒性抑制的能力。在另一系列实验中,腹腔注射ST-421完全抑制了nu/nu小鼠体内人肿瘤异种移植瘤的生长,并且这种抑制活性紧密依赖于细胞表面二聚体Le(a)抗原的表达。虽然Le(a)抗原在nu/nu小鼠的肾脏中表达,但向这些小鼠输注ST-421并未引起肾脏组织的组织学变化。这一发现表明该单克隆抗体不会损害含有交叉反应性Le(a)抗原的正常细胞或组织。这些结果表明,ST-4在体外和体内均发挥显著的抗肿瘤作用,不影响正常组织上表达的Le(a)抗原,因此在治疗某些表达二聚体Le(a)抗原的人类癌症类型方面具有潜在应用价值。